Co–Operations Claris Lifesciences forms Joint Venture with Otsuka and Mitsui

Editor: Dominik Stephan

Claris Lifesciences Ltd, India (Claris) has announced the completion of the transfer of its Infusion business for India and Emerging Markets to the Joint Venture (Claris-Otsuka) with Otsuka Pharmaceutical Factory Inc, Japan (OPF) and Mitsui & Co Ltd, Japan (Mitsui).

Related Companies

(Picture: PROCESS)

Ahemedabad/India – The Infusion business includes common solutions, anti-infective, plasma volume expanders and parenteral nutrition therapies for India and emerging markets. The company has transferred two of its existing plants to the Joint Venture. It will continue to have a 20% stake in the joint venture while Otsuka and Mitsui will hold 60% and 20%, respectively. Claris has received a total cash consideration of Rs. 1,050 crore as a part of the transaction from Claris-Otsuka and is valued at Rs. 1,313 crore.

This is in the Pipeline for the New Joint–Venture:

  • The Company has used the part of the cash consideration towards debt prepayment of around Rs. 360 crore;
  • Subject to regulatory approvals; the Company intends to reward shareholders via buyback of shares. The Company has allocated Rs. 300 crore for the buyback of shares.
  • The remaining funds net of taxes and deal related expenses will be used to fund the future growth of the company.

Subscribe to the newsletter now

Don't Miss out on Our Best Content

By clicking on „Subscribe to Newsletter“ I agree to the processing and use of my data according to the consent form (please expand for details) and accept the Terms of Use. For more information, please see our Privacy Policy.

Unfold for details of your consent